About Perseus Proteomics
Perseus Proteomics is a company based in Erimo (Japan) founded in 2001 was acquired by Fujifilm in February 2009. The company has 32 employees as of March 31, 2024. Perseus Proteomics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
- Headquarter Erimo, Japan
- Employees 32 as on 31 Mar, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Perseus Proteomics, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Perseus Proteomics
Perseus Proteomics is a publicly listed company on the TSE with ticker symbol 4882 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Funding Insights of Perseus Proteomics
Investors in Perseus Proteomics
Perseus Proteomics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Fujifilm.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by the venture capital firm.
|
Locked | Locked | Locked |
Investor details for Perseus Proteomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Perseus Proteomics
Investment portfolio details for Perseus Proteomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Perseus Proteomics
Detailed financials for Perseus Proteomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Perseus Proteomics Comparisons
Peer comparison for Perseus Proteomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Perseus Proteomics
Perseus Proteomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, Revolution Medicines and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Perseus Proteomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Perseus Proteomics
Complete news archive for Perseus Proteomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Perseus Proteomics
Perseus Proteomics was founded in 2001 and raised its 1st funding round 5 years after it was founded.
Perseus Proteomics is headquartered in Erimo, Japan. It is registered at Erimo, Hokkaido, Japan.
As of Mar 31, 2024, the latest employee count at Perseus Proteomics is 32.
Annual revenue of Perseus Proteomics is $805.58K as on Mar 31, 2025.
Perseus Proteomics was founded in 2001 in Erimo, Japan, within the biotechnology sector. Antibody-based therapeutics and diagnostic reagents are developed for cancer, using disease analysis, transcriptome data, and bioinformatics to target overexpressed surface antigens on malignant cells or blood biomarkers signaling disease states. These tools support drug discovery screening, diagnostic imaging for radiation therapy, antibody-delivered cancer treatments, and biomarker detection for diagnosis, prognosis, and outcome monitoring.
Perseus Proteomics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Yes, Perseus Proteomics is publicly traded on TSE under the ticker symbol 4882.
Perseus Proteomics has 1 investor. Key investors include Fujifilm.
The ticker symbol of Perseus Proteomics is 4882 on TSE.